Cellectis (CLLS) Projected to Post Earnings on Thursday

Cellectis (NASDAQ:CLLS) is anticipated to announce its H1 2026 results after the market closes on Thursday, August 6th. Analysts expect Cellectis to announce earnings of ($0.2630) per share and revenue of $11.05 million for the quarter. Interested persons can find conference call details on the company’s upcoming H1 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 11:40 AM ET.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.08. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.04 million.

Cellectis Stock Performance

Shares of NASDAQ:CLLS opened at $2.77 on Wednesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.52 and a quick ratio of 1.52. The business’s fifty day moving average price is $3.00 and its two-hundred day moving average price is $3.50. Cellectis has a fifty-two week low of $2.48 and a fifty-two week high of $5.48. The stock has a market capitalization of $277.94 million, a price-to-earnings ratio of -4.13 and a beta of 2.91.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Global Retirement Partners LLC acquired a new position in Cellectis during the 4th quarter worth about $34,000. Acadian Asset Management LLC increased its position in Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 26,461 shares in the last quarter. Virtu Financial LLC acquired a new stake in Cellectis in the 3rd quarter valued at about $72,000. Millennium Management LLC raised its stake in shares of Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 22,080 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Cellectis in the third quarter worth about $633,000. 63.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CLLS has been the topic of several recent analyst reports. Barclays assumed coverage on shares of Cellectis in a research note on Thursday, May 28th. They issued an “overweight” rating and a $9.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $8.00 price target on shares of Cellectis in a report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.